Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Epilepsy With Simple or Complex Partial Onset Seizures
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 82 more
Conditions
SCAR
Interventions
Blood or Saliva
Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
Not listed
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Partial Epilepsy
Interventions
800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
16 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
106
States / cities
Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 82 more
Conditions
Epilepsy
Interventions
Eslicarbazepine, Carbamazepine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

NCT02283788
Conditions
Epilepsy
Interventions
BIA 2-093, Moxifloxacin, Placebo
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Conditions
Epilepsy With Partial On-set Seizures
Interventions
Eslicarbazepine Acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Mobile, Alabama • Phoenix, Arizona • Downey, California + 46 more
Conditions
Epilepsy
Interventions
Placebo, BIA 2-093 3000 mg once daily, BIA 2-093 3600 mg once daily
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Miramar, Florida
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
4 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Henderson, Nevada
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate 1600 mg, Eslicarbazepine acetate 1200 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
39
States / cities
Tucson, Arizona • Conway, Arkansas • Little Rock, Arkansas + 34 more
Conditions
Epilepsy
Interventions
blood draw
Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
7
States / cities
Sun City, Arizona • Boise, Idaho • Lexington, Kentucky + 4 more
Completed Phase 3 Interventional Results available

Eslicarbazepine Acetate Monotherapy Long Term Study

NCT00910247
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
96
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more